7-fluoro-1-methyl-3,4-dihydro-2H-quinoxaline | 1354953-50-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 7-fluoro-1-methyl-3,4-dihydro-2H-quinoxaline
• 英文别名: 7-Fluoro-1-methyl-1,2,3,4-tetrahydroquinoxaline；6-fluoro-4-methyl-2,3-dihydro-1H-quinoxaline
• CAS: 1354953-50-6
• 化学式: C₉H₁₁FN₂
• mdl: MFCD20731130
• 分子量: 166.198
• InChiKey: OKDVTYCZSDCCHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-fluoro-1-methyl-3,4-dihydro-2H-quinoxaline 、 7-bromo-9-chloro-4-[(2-methoxypyrimidin-5-yl)methyl]-3,5-dihydro-2H-1,4-benzoxazepine 在 2-双环己基膦-2',6'-双(二甲基氨基)-1,1'-联苯 、 [(2-dicyclohexylphosphino-2’,6’-bis(N,N-dimethylamino)-1,1‘-biphenyl)-2-(2’-amino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 以3 %的产率得到9-chloro-7-(6-fluoro-4-methyl-2,3-dihydroquinoxalin-1-yl)-4-[(2-methoxypyrimidin-5-yl)methyl]-3,5-dihydro-2H-1,4-benzoxazepine
  参考文献：
  名称：

  [EN] EP2 ANTAGONIST COMPOUNDS
  [FR] COMPOSÉS ANTAGONISTES D'EP2

  摘要：

  Described herein are compounds that are EP2 antagonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditionsassociated with EP2 activity.

  公开号：

  WO2022272060A1
• 作为产物：
  描述：

  6-fluoro-4-methyl-1,3-dihydroquinoxalin-2-one 在 硼烷四氢呋喃络合物 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 7-fluoro-1-methyl-3,4-dihydro-2H-quinoxaline
  参考文献：
  名称：

  EP2 ANTAGONIST COMPOUNDS

  摘要：

  Disclosed herein are compounds that are EP2 antagonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditions associated with EP2 activity.

  公开号：

  WO2024145259A2

文献信息

• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• Fused thiazolopyrimidine derivatives as MNKS inhibitors
  申请人：LIFEARC

  公开号：US10669284B2

  公开（公告）日：2020-06-02

  The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.

  本发明涉及式 I 和 H 的化合物或其药学上可接受的盐或酯。本发明的其他方面涉及所述化合物在治疗细胞生长、增殖和/或存活失控疾病、不适当的细胞免疫反应、不适当的细胞炎症反应或神经退行性疾病（优选牛磺酸病，更优选阿尔茨海默病）中的药物组合物和治疗用途。
• Compounds for the treatment of cancer and inflammatory disease
  申请人：SHY Therapeutics LLC

  公开号：US10870657B2

  公开（公告）日：2020-12-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供的化合物可抑制 MAPK 磷酸化，因此可用于治疗癌症和炎症性疾病的组合物和方法中。
• Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
  申请人：Shy Therapeutics LLC

  公开号：US10940139B2

  公开（公告）日：2021-03-09

  Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

  本文提供了通过化合物与 Ras 超家族蛋白（在某些情况下包括 K-Ras 及其突变体）的 GTP 结合结构域结合，治疗涉及 Ras 超家族信号异常的癌症、炎症性疾病、rasopathies 和纤维化疾病的方法和组合物，以及检测此类组合物的新方法。
• Fused thiazolopyrimidine derivatives as MNKs inhibitors
  申请人：LIFEARC

  公开号：US11136338B2

  公开（公告）日：2021-10-05

  The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably. Alzheimer's disease.

  本发明涉及式 I 和 H 的化合物或其药学上可接受的盐或酯。本发明的其它方面涉及所述化合物在治疗细胞生长、增殖和/或存活失控疾病、不适当的细胞免疫反应、不适当的细胞炎症反应或神经退行性疾病（优选牛磺酸病，甚至更优选）中的药物组合物和治疗用途。阿尔茨海默病。